AIMS: To investigate whether nifedipine affects ocular perfusion or visual fields in open angle glaucoma patients. METHODS: In a parallel group study nifedipine or placebo was administered for 3 months (n = 30). Ocular fundus pulsation amplitude (FPA), cup blood flow (Flowcup) andvisual field mean deviation (MD) were measured. RESULTS: Five patients receiving nifedipine discontinued due to adverse events. Nifedipine did not affect FPA [difference: 0.3 microm (95% CI -0.3,0.9); P = 0.70], Flowcup: [difference: -9 rel.units (95% CI -133,114); P = 0.99], or MD [difference: 0.2dB (95% CI -2.2,2.7); P = 0.51] vs placebo. CONCLUSIONS:Systemic nifedipine is not well tolerated in glaucoma patients and exerts no effect on visual fields or ocular perfusion.
RCT Entities:
AIMS: To investigate whether nifedipine affects ocular perfusion or visual fields in open angle glaucomapatients. METHODS: In a parallel group study nifedipine or placebo was administered for 3 months (n = 30). Ocular fundus pulsation amplitude (FPA), cup blood flow (Flowcup) and visual field mean deviation (MD) were measured. RESULTS: Five patients receiving nifedipine discontinued due to adverse events. Nifedipine did not affect FPA [difference: 0.3 microm (95% CI -0.3,0.9); P = 0.70], Flowcup: [difference: -9 rel.units (95% CI -133,114); P = 0.99], or MD [difference: 0.2dB (95% CI -2.2,2.7); P = 0.51] vs placebo. CONCLUSIONS: Systemic nifedipine is not well tolerated in glaucomapatients and exerts no effect on visual fields or ocular perfusion.
Authors: L Schmetterer; S Dallinger; O Findl; K Strenn; U Graselli; H G Eichler; M Wolzt Journal: Invest Ophthalmol Vis Sci Date: 1998-06 Impact factor: 4.799
Authors: A Luksch; G Rainer; D Koyuncu; P Ehrlich; T Maca; M E Gschwandtner; C Vass; L Schmetterer Journal: Br J Ophthalmol Date: 2005-01 Impact factor: 4.638